Ardea Biosciences, Inc., of San Diego, California, is a biotechnology
company focused on the discovery and development of small-molecule
therapeutics for the treatment of HIV, gout, cancer and inflammatory
diseases. We have five product candidates in clinical trials and others in
preclinical development and discovery. Our most advanced product candidate
is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which
has successfully completed a Phase 2a study for the treatment of patients
with HIV. We have evaluated our second-generation NNRTI for the treatment
of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have
selected it for clinical development. RDEA594, our lead product candidate
for the treatment of gout, is being evaluated in a Phase 1 clinical trial
and is believed to be an inhibitor of the URAT1 transporter in the kidney,
which is responsible for regulation of uric acid levels. We are evaluating
our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer
patients, and have completed a Phase 1 study in normal healthy volunteers
as a precursor to trials in patients with inflammatory diseases. Lastly, we
have evaluated our second-generation MEK inhibitor for the treatment of
cancer and inflammatory diseases, RDEA436, in a human micro-dose
pharmacokinetic study and have selected it for clinical development.

Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements. Such statements include, but are not limited to, statements
regarding our goals, including the expected properties and benefits of
RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the
results of preclinical, clinical and other studies. Risks that contribute
to the uncertain nature of the forward- looking statements include: risks
related to the outcome of preclinical and clinical studies, risks related
to regulatory approvals, delays in commencement of preclinical and clinical
studies, and costs associated with our drug discovery and development
programs and business development activities. These and other risks and
uncertainties are described more fully in our most recently filed SEC
documents, including our Annual Report on Form 10-K and our Quarterly
Reports on Form 10-Q, under the headings "Risk Factors." All
forward-looking statements contained in this press release speak only as of
the date on which they were made. We undertake no obligation to update such
statements to reflect events that occur or circumstances that exist after
the date on which they were made.

(Date:12/8/2016)... ... , ... This CAST literature review and report looks at problems caused by ... economic effects in countries that are major global commodity exporters and importers, which show ... of low level presence (LLP) puts large volumes of trade worth billions of dollars ...

(Date:6/27/2016)... , June 27, 2016 Research and Markets ... America 2016-2020" report to their offering. ... North America to grow at a CAGR of 12.28% ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...

(Date:6/22/2016)... On Monday, the Department of Homeland Security (DHS) issued ... the Biometric Exit Program. The Request for Information (RFI), ... that CBP intends to add biometrics to confirm when ... , in order to deter visa overstays, to ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...